Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: mycophenolate mofetil hydrochloride

« Back to Dashboard
Mycophenolate mofetil hydrochloride is the generic ingredient in one branded drug marketed by Roche Palo and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are thirty-three drug master file entries for mycophenolate mofetil hydrochloride. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: mycophenolate mofetil hydrochloride

Drug Master File Entries: see list33
Suppliers / Packaging: see list1

Pharmacology for Ingredient: mycophenolate mofetil hydrochloride


Applicant Application No. Form Dosage
<disabled><disabled>INJECTABLE; INJECTION500MG

Clinical Trials for: mycophenolate mofetil hydrochloride

Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Status: Terminated Condition: Stable Renal Transplant Recipients

A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .
Status: Terminated Condition: Interstitial Cystitis; Painful Bladder Syndrome

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
Status: Completed Condition: Systemic Lupus Erythematosus; Arthritis

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
Status: Not yet recruiting Condition: Interstitial Lung Disease; ILD; Systemic Sclerosis; Scleroderma

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
Status: Completed Condition: Autoimmune Disease

Influence of Pantoprazole to the Bioavailability of Myfortic® and CellCept®
Status: Recruiting Condition: Immunosuppressive Medication After Renal Transplantation; Concomitant Medication After Renal Transplantation

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche Palo
mycophenolate mofetil hydrochloride
INJECTABLE;INJECTION050758-001Aug 12, 1998RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn